Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

CELU - Celularity Inc

Previous close
2.29
0   0%

Share volume: 0
Last Updated: Thu 26 Dec 2024 03:24:59 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 3.82%

PREVIOUS CLOSE
CHG
CHG%
$2.29
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
27%
Profitability 0%
Dept financing 18%
Liquidity 7%
Performance 62%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.15%
1 Month
-24.00%
3 Months
-21.38%
6 Months
-24.00%
1 Year
1,166.67%
2 Year
98.26%
Key data
Stock price
$2.29
P/E Ratio 
-0.34
DAY RANGE
$2.33 - $2.85
EPS 
-$110.20
52 WEEK RANGE
$0.29 - $7.97
52 WEEK CHANGE
$34.59
MARKET CAP 
67.713 M
YIELD 
N/A
SHARES OUTSTANDING 
21.985 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.51
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$83,328
AVERAGE 30 VOLUME 
$225,027
Company detail
CEO: Robert Joseph Hariri Gordon
Region: US
Website: celularity.com
Employees: 220
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Celularity Inc. develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

Recent news